General Information of DTT (ID: TT2UE56)

DTT Name Sodium/glucose cotransporter 1 (SGLT1) DTT Info
Gene Name SLC5A1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sotagliflozin DMMLXA9 Heart failure BD10-BD13 Approved [1]
------------------------------------------------------------------------------------
5 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
LIK-066 DM32NWD Heart failure BD10-BD13 Phase 2 [2]
YG1699 DM1NR1J Type-1 diabetes 5A10 Phase 2 [3]
1614235 + 2330672 DMD751X Type-2 diabetes 5A11 Phase 1 [2]
GSK1614235 DM7I1AQ Type-2 diabetes 5A11 Phase 1 [4]
LX2761 DM8ZS7T Type 2 diabetes 5A11 Phase 1 [5]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
T-1095 DMGFS51 Diabetic complication 5A2Y Discontinued in Phase 2 [6]
------------------------------------------------------------------------------------
18 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
10-methoxy-N(1)-methylburnamine-17-O-veratrate DMJW25X Discovery agent N.A. Investigative [7]
Acerogenin A DM4BWMO Discovery agent N.A. Investigative [8]
ACEROGENIN B DMVQ30P Discovery agent N.A. Investigative [8]
Alstiphyllanine D DM2FLDJ Discovery agent N.A. Investigative [7]
Alstiphyllanine E DMTNQ5E Discovery agent N.A. Investigative [7]
Alstiphyllanine F DMKRAEW Discovery agent N.A. Investigative [7]
Burnamine-17-O-3',4',5'-trimethoxybenzoate DMBO0WI Discovery agent N.A. Investigative [7]
KURAIDIN DMLDUJ1 Discovery agent N.A. Investigative [9]
KURARINONE DMH0G8W Discovery agent N.A. Investigative [9]
Kushenol N DMY13UR Discovery agent N.A. Investigative [9]
O-spiroketal glucoside DM3FS62 Discovery agent N.A. Investigative [10]
Phlorizin DMNARGO Discovery agent N.A. Investigative [11]
QCP DM62PI8 Discovery agent N.A. Investigative [12]
QCPac DMSMQXZ Discovery agent N.A. Investigative [12]
QNEQCPQVSac DMTY5HP Discovery agent N.A. Investigative [12]
QSPac DMJHTUG Discovery agent N.A. Investigative [12]
sergliflozin DMF8GAX Discovery agent N.A. Investigative [13]
Sophoraflavanone G DMBTMN5 Discovery agent N.A. Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Investigative Drug(s)
Molecule Interaction Atlas

References

1 LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
3 ClinicalTrials.gov (NCT04956263) A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes. U.S.National Institutes of Health.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
6 T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
7 Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
8 Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
9 Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
10 ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.
11 J Biol Chem. 1988 Jan 5;263(1):187-92.High affinity phlorizin binding to the LLC-PK1 cells exhibits a sodium:phlorizin stoichiometry of 2:1.
12 Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13.
13 Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal gluco... J Pharmacol Exp Ther. 2007 Jan;320(1):323-30.